Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CERo Therapeutics Holdings ( (CERO) ) has issued an update.
On November 26, 2025, CERo Therapeutics Holdings entered into a new purchase agreement with an institutional investor, allowing the company to issue and sell up to $14.6 million of its common stock. This agreement is a continuation of previous purchase agreements, aiming to raise a total of $25 million. The arrangement includes provisions for fixed and variable price purchases, with limitations on the investor’s ownership percentage to ensure compliance with regulatory requirements. This strategic move is expected to bolster the company’s financial position and provide flexibility in its capital-raising efforts.
The most recent analyst rating on (CERO) stock is a Hold with a $0.10 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is engaged in issuing and selling its common stock to institutional investors as part of its financial strategy.
Average Trading Volume: 1,869,787
Technical Sentiment Signal: Sell
Current Market Cap: $1.48M
See more data about CERO stock on TipRanks’ Stock Analysis page.